{"filing":{"accession_number":"0001628280-26-038630","cik":"0001706431","ticker":"VIR","company_name":"Vir Biotechnology, Inc.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"vir-20260525.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/vir-20260525.htm"},"events":[{"id":1957,"run_id":1700,"accession_number":"0001628280-26-038630","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Saira Ramasastry, a Board member and Audit Committee Chair, resigned effective May 26, 2026, due to a business conflict. Her departure affects board composition and audit oversight governance.","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-05-28","items":[{"id":2490,"accession_number":"0001628280-26-038630","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Saira Ramasastry, a Board member and Audit Committee Chair, resigned effective May 26, 2026, due to a business conflict. While the filing also discloses Robert More's appointment as the new Audit Committee Chair, the principal disclosed action is Ms. Ramasastry's departure from the Board. The resignation of an Audit Committee Chair is material to investors as it affects board composition and audit oversight governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:49:14.532812+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":1958,"run_id":1700,"accession_number":"0001628280-26-038630","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Vir Biotechnology held its 2026 Annual Meeting on May 26, 2026, with shareholder votes on three proposals: election of Class I directors (Robert More, Janet Napolitano, Elliott Sigal), advisory vote on executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor.","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-05-28","items":[{"id":2491,"accession_number":"0001628280-26-038630","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Vir Biotechnology's 2026 Annual Meeting held on May 26, 2026, covering three proposals: election of Class I directors (Robert More, Janet Napolitano, Elliott Sigal), advisory vote on executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing presents final voting tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:49:14.532812+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2490,"accession_number":"0001628280-26-038630","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Saira Ramasastry, a Board member and Audit Committee Chair, resigned effective May 26, 2026, due to a business conflict. While the filing also discloses Robert More's appointment as the new Audit Committee Chair, the principal disclosed action is Ms. Ramasastry's departure from the Board. The resignation of an Audit Committee Chair is material to investors as it affects board composition and audit oversight governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:49:14.532812+00:00","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-05-28"},{"id":2491,"accession_number":"0001628280-26-038630","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Vir Biotechnology's 2026 Annual Meeting held on May 26, 2026, covering three proposals: election of Class I directors (Robert More, Janet Napolitano, Elliott Sigal), advisory vote on executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing presents final voting tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:49:14.532812+00:00","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-05-28"}]}